Strive Health Pitch Deck: All 14 Slides + Teardown

Executive Summary: The $166M Value-Based Play

Strive Health’s pitch deck is a clinical study in how to present a complex healthcare solution to institutional investors. According to publisher-reported facts from Business Insider, the company raised $166M in a 2023 Series C round. The deck itself, spanning 14 slides, focuses on the transition from fee-for-service dialysis to a value-based model that emphasizes early intervention and home-based care. By framing the problem as a $410B systemic failure, Strive Health positions its technology and elite management team as the only logical solution for payors and at-risk providers.

Slide 1: The Face of the Company

The deck opens with a high-resolution headshot of Chris Riopelle , the Chief Executive Officer and Co-Founder. In high-stakes healthcare fundraising, the pedigree of the founder is often as important as the technology. Riopelle’s presence here signals a 'founder-led' narrative, which is reinforced in later slides by his extensive background in the renal care industry.

Slide 2: Strive Health at a Glance

Slide 2 serves as the 'Executive Summary' slide. It breaks the company down into four pillars: Purpose, Platform, Partnerships, and Team. Under Purpose , the deck states that the current kidney care system is 'broken' and that there is '>$410B of unmanaged spend on late-stage CKD & ESRD patients in the U.S.' The Platform section introduces the 'home-first dialysis' model. The Partnerships section lists heavyweights like Humana, SSM Health, and Blue Cross Blue Shield . Finally, the Team section highlights backing from NEA, Town Hall Ventures, and Ascension Ventures . This slide successfully establishes credibility before the investor even sees the product.

Slide 4: The Unmatched Management Team

Slide 4 is perhaps the strongest slide in the deck for a Series C round. It features eight executives, each accompanied by logos of their former employers. The list is a 'who’s who' of healthcare: DaVita, Optum, Deloitte, Evolent Health, and CareMore . By showing that the leadership comes from the very companies they are now disrupting or partnering with, Strive Health mitigates 'execution risk' in the eyes of investors. The headline explicitly claims an 'unmatched combination of kidney care operations, value-based care, and technology experience.'

Slide 6: Market Opportunity and TAM

Slide 6 quantifies the opportunity. It breaks down the Total Addressable Market (TAM) into three segments: $213B from patients already diagnosed with kidney disease, and an 'Incremental from Undiagnosed Patients' of $199B , totaling a $412B TAM . The slide also notes an additional $200B upside from servicing Stage 1-2 patients. The right side of the slide lists growth drivers: rising comorbidities (diabetes and hypertension), aging demographics, and decreasing mortality rates. This data, sourced from LEK analysis, provides the 'why now' for the investment.

Slide 8: Business & Platform Transition

Slide 8 is a simple transition slide titled 'Business & Platform.' While it contains no data, it signals a shift from the 'Why' (market and team) to the 'How' (technology and operations). In a 14-slide deck, these transitions help maintain a narrative flow, ensuring the investor isn't overwhelmed by a sudden shift in topic.

Slide 10: The CareMultiplier™ Data Platform

Slide 10 dives into the technical moat. It describes the CareMultiplier Platform as a three-step process. First, it aggregates data from claims, eligibility, encounters, and third parties (labs/pharmacy). Second, it interprets this data using 'Proprietary machine learning, and artificial intelligence' trained on '50M+ Public patient records.' Third, it delivers actionable insights to the 'Kidney Hero suite' and 'Population Health Analytics Tool.' The slide notes that 200k lives are already hosted on the platform, proving that the technology is not just theoretical but operating at scale.

Slide 12: Operations and Initial Results

Slide 12 provides the 'proof of life.' It shows a timeline of five partnership launches between April 2020 and January 2021 , including SSM Health, Humana, Conviva, and Independence Blue Cross . The right side of the slide features three key metrics: 15K Total Lives , 7K+ KidneyHero Touchpoints , and $850M Patient spend under management . These figures are crucial for a Series C deck, as they demonstrate that the company has moved past the pilot phase and is successfully managing significant capital.

What Strive Health Does Well

The Strive Health deck is a masterclass in Authority Signaling . In the healthcare sector, where regulatory and operational hurdles are immense, investors look for teams that have 'been there, done that.' By placing the team slide (Slide 4) early and decorating it with logos like DaVita and Optum, Strive Health immediately answers the question of whether they are capable of navigating the complex U.S. healthcare landscape.

Furthermore, the TAM Visualization on Slide 6 is excellent. Instead of just providing a single large number, they segment the market by patient stage (CKD 3, CKD 4-5, ESRD) and diagnosis status. This shows a deep understanding of the patient funnel and suggests multiple avenues for growth, from managing existing sick patients to early intervention for the undiagnosed.

Finally, the Platform Architecture on Slide 10 strikes a balance between high-level strategy and technical detail. It explains the data inputs, the processing engine (ML/AI), and the clinical outputs without getting bogged down in code or jargon. The mention of 50 million records used for training is a specific, impressive metric that builds confidence in their machine learning capabilities.

What is Missing from the Deck

Despite its strengths, the deck has notable omissions that are common in later-stage fundraising materials intended for a broader audience. First, there is no 'Ask' slide . While we know from publisher reports that they raised $166M, the deck does not explicitly state the funding goal or how the capital will be allocated (e.g., geographic expansion, R&D, or sales). This suggests the deck may have been used as a general presentation or that the 'Ask' was handled in a separate, more confidential document.

Second, the deck is light on Unit Economics . While it mentions $850M in spend under management, it does not disclose the percentage of savings Strive Health keeps, their customer acquisition cost (CAC), or the lifetime value (LTV) of a partnership. For a Series C round, investors typically want to see a clear path to profitability and a breakdown of how the value-based contracts are structured.

Third, there is no Competitor Analysis . The kidney care space is increasingly crowded with players like Cricket Health and Somatus, not to mention the incumbents like DaVita and Fresenius who are also moving toward value-based models. Strive Health relies on its 'market leader' claim without showing a side-by-side comparison of why their platform is superior to other emerging tech-enabled providers.

Lessons for Founders

Founders in complex industries should take note of how Strive Health handles Partnership Validation . On Slide 12, they don't just list logos; they provide a timeline of when those partnerships went live. This creates a sense of momentum and 'social proof' that is incredibly persuasive. If major payors like Humana are trusting Strive with their patient populations, it signals to investors that the product has passed rigorous clinical and security audits.

Another takeaway is the Problem-Solution Alignment . The deck starts with the 'broken' system and the 'unsustainable cost trends' (Slide 2) and ends with the 'Kidney Hero' clinical touchpoints (Slide 12). The narrative arc is clear: the system is failing, the costs are astronomical, and Strive’s technology-plus-human-touch model is the specific remedy for those costs.

Lastly, the use of Third-Party Data (LEK Analysis on Slide 6) to support market claims is a best practice. It removes the 'founder bias' from the market sizing and shows that the company’s strategy is aligned with broader industry research. For any founder pitching a large-scale enterprise or healthcare solution, backing up your TAM with reputable external sources is a requirement, not an option.